Conduit Pharmaceuticals Inc. (CDT) Key Metrics
CDT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $264,373
- Enterprise value
- $2.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.56
CDT key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCDT returns How much profit the business earns on the capital it uses.
CDT financial health Debt, liquidity and how easily interest is covered.
CDT efficiency & capital use Working capital cycle and where the cash goes.
CDT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CDT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CDT cash returned to shareholders
CDT key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Share price at fiscal year-end | $8,000.00 | $997,500.00 | $997,500.00 | $997,500.00 | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −6.2% | — | — | — | — |
| Return on invested capital (ROIC) | −2.7% | — | — | — | — |
| Return on assets (ROA) | −2.2% | −311.9% | −14.8% | — | — |
| Return on tangible assets | −1.9% | — | −7.4% | — | — |
| Free cash flow margin | −0.7% | −1.1% | — | — | — |
| Financial health | |||||
| Total debt | $1.29B | $7.5M | $985,000 | $2.0M | $177,057 |
| Cash & short-term investments | $389.9M | $554,000 | $4.2M | $345,777 | $48,555 |
| Net debt | $895.8M | $6.9M | −$3.2M | $1.7M | $128,502 |
| Debt / equity | 1.02 | — | — | — | 8.59 |
| Debt / assets | 0.36 | 1.78 | 0.14 | 402.00 | 0.83 |
| Net debt / EBITDA | — | — | −1.06 | — | — |
| Current ratio | 1.93 | 0.25 | 3.18 | 0.15 | 0.54 |
| Quick ratio | 1.36 | −31.69 | 3.18 | 0.15 | 0.54 |
| Interest coverage | -115.2 | -10.2 | -24.9 | — | — |
| Working capital | $651.9M | −$8.0M | $3.9M | −$3.5M | −$88,343 |
| Invested capital | $2.16B | $110,000 | −$3.7M | −$8.4M | $149,121 |
| Tangible asset value | −$172.2M | −$1.44B | −$457,000 | −$10.1M | $20,619 |
| Net current asset value | −$929.8M | −$8.3M | −$1.9M | −$9.4M | −$88,343 |
| Capital allocation | |||||
| Dividends paid | $8.0M | $8.2M | — | — | — |
| Share buybacks (net) | $106,000 | $0 | — | — | — |
| Capex / revenue | 0.1% | 0.0% | — | — | — |
| Capex / depreciation | 0.99 | 0.11 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 0.1% | 0.2% | — | — | — |
| R&D / revenue | 0.2% | 0.4% | — | — | — |
| SG&A / revenue | 1.2% | 1.3% | — | — | — |
| Efficiency | |||||
| Days sales outstanding | 31.1 | 0.2 | — | — | — |
| Days of inventory on hand | 80.8 | 274,028.7 | — | — | — |
| Days payables outstanding | 39.3 | 656.1 | — | — | — |
| Cash conversion cycle (days) | 72.6 | 273,372.8 | — | — | — |
| Receivables turnover | 11.72 | 1,885.93 | — | — | — |
| Payables turnover | 9.28 | 0.56 | — | — | — |
| Inventory turnover | 4.52 | 0.00 | — | — | — |
| Asset turnover | 1.53 | 161.55 | 0.00 | 0.00 | 0.00 |
| Average receivables | $231.7M | $489,000 | — | — | — |
| Average payables | $181.4M | $821,500 | $107,500 | $0 | — |
| Average inventory | $372.7M | $343.1M | — | — | — |
| Intangibles / total assets | 40.5% | 34,289.3% | 0.0% | 100.0% | 0.0% |
Computed from CDT's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CDT valuation and financial ratios
Conduit Pharmaceuticals earned a return on equity of −6.2% and a return on invested capital of −2.7% in fiscal 2025. It ended the year with $1.3 billion of debt and $389.9 million in cash and short-term investments, net debt of $895.8 million. It returned $8.1 million to shareholders: $8.0 million in dividends and $0.1 million in share buybacks.
See the CDT income statement, the CDT chart for price history, or the CDT stock overview for the latest quote and news.
CDT key metrics FAQ
What is Conduit Pharmaceuticals's return on equity?
Conduit Pharmaceuticals's return on equity (ROE) was −6.2% in fiscal 2025: net income of -$39.2 million on average shareholders' equity of $628.8 million.
What is Conduit Pharmaceuticals's ROIC?
Conduit Pharmaceuticals's return on invested capital was −2.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Conduit Pharmaceuticals have?
Conduit Pharmaceuticals had total debt of $1.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.02.
Does Conduit Pharmaceuticals buy back its shares?
Yes. Conduit Pharmaceuticals spent $0.1 million on net share repurchases in fiscal 2025.
What is Conduit Pharmaceuticals's current ratio?
Conduit Pharmaceuticals's current ratio was 1.93 at the end of fiscal 2025: current assets were 1.93 times current liabilities.